-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmuPharma Enlists Kymos as CRO Partner for Kapiglucagon Program

MT Newswires·08/10/2026 04:17:56
Listen to the news
04:17 AM EDT, 08/10/2026 (MT Newswires) -- ImmuPharma (IMM.L) selected Kymos Germany/Prolytic as the bioanalytical contract research organization, or CRO, partner for its Kapiglucagon program following a competitive tender process. The CRO will support the development and validation of regulated bioanalytical methods for the glucagon prodrug, including analysis of samples from the nonclinical and phase 1 clinical programs, according to a Monday filing.